Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism : a Prospective FDG PET Study
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before immunomodulating treatment, or within 10 days of treatment initiation.
• Age ≥ 18 years old
• Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following criteria :
‣ Definite limbic autoimmune encephalitis according to 2016 Graus et al. criteria
⁃ Possible autoimmune encephalitis according to 2016 Graus et al. criteria AND typical autoantibody detected in serum or CSF
⁃ Probable or certain paraneoplastic neurological syndrome according to Graus et al. 2021 criteria (excluding peripheral neurological syndromes)
• Less than 6 months since first neurological symptoms imputable to autoimmune encephalitis
• Affiliated or entitled to a social security system (except AME)
• Obtaining free, written and informed consent (patient or legal representative or the close relative)